Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Time to Sell?

Key Points

• Telix Pharmaceuticals hit a new 52-week low trading at $12.90 before closing at $13.59 with a trading volume of 55,378 shares.
• Analysts from HC Wainwright, Wedbush, and William Blair have provided positive ratings, setting price targets of $23.00 and $22.00 respectively, suggesting potential for growth.
• Recent institutional investments included new stakes worth between $170,000 and $451,000 by several firms, indicating interest in TLX despite its current price drop.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $12.90 and last traded at $13.59, with a volume of 55378 shares traded. The stock had previously closed at $13.59.

Wall Street Analyst Weigh In

Several research firms have issued reports on TLX. HC Wainwright began coverage on shares of Telix Pharmaceuticals in a research report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price target on the stock. Wedbush restated an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. Finally, William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th.

Telix Pharmaceuticals Stock Down 3.7%

The business's fifty day moving average price is $15.59 and its 200 day moving average price is $16.75. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99.

Hedge Funds Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals during the 1st quarter worth about $170,000. Blair William & Co. IL bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $217,000. Vanguard Personalized Indexing Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $297,000. ABC Arbitrage SA bought a new position in Telix Pharmaceuticals during the 1st quarter valued at about $451,000. Finally, Pier Capital LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $3,037,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.